NCT04111666View on ClinicalTrials.gov

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 14, 2019

Primary Completion Date

June 9, 2022

Study Completion Date

June 9, 2022

Conditions
Healthy
Interventions
BIOLOGICAL

AL101

Active dose of AL101

OTHER

Placebo

Saline solution administered as a single and multiple infusion as placebo.

Trial Locations (2)

32806

Study site, Orlando

33126

Study site, Miami

Sponsors

Lead Sponsor

Alector Inc.
All Listed Sponsors
lead

Alector Inc.

INDUSTRY

NCT04111666 - A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | Biotech Hunter | Biotech Hunter